Pharmacogenomics in Psychiatry
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: closed (20 July 2019) | Viewed by 12170
Special Issue Editors
Interests: pharmacogenomics; pre-emptive pharmacogenomics; personalized medicine; genomics; schizophrenia; bipolar disorder; major depression; antipsychotics; antidepressants; lithium; implementation of pharmacogenomics in psychiatric clinical practice; CYP2D6; CYP2C19
Interests: pharmacogenomics; psychopharmacology; psychopathology; psychosis; schizophrenia; mood disorders; personality disorders
2. Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain P.O. Box 15551, United Arab Emirates
3. Clinical Bioinformatics Unit, Department of Pathology, School of Medicine and Health Sciences, Erasmus University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
Interests: pharmacogenomics; personalized therapeutics; clinical care; clinical implementation; clinical studies; pharmacogenomic testing; health technology assessment; regulatory guidance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pharmacogenomics is a fascinating field, which refers to the impact of multiple genes and specific genetic variations on drug pharmacokinetics and pharmacodynamics, which in turn can lead to clinically essential variations in efficacy, but also, in adverse drug reactions. Owing to the advances in genomics technology, particularly with the advent of whole genome sequencing approaches the field has witnessed significant progress over the last years, further supporting the efforts for precision medicine. Particularly for psychiatry, which involves chronic and severely disabling diseases, this is the most crucial, as well as a challenging, target. Until now, there are very few studies highlighting the clinical implementation of pharmacogenomics in psychiatry.
It seems therefore that the implementation of the present special issue, focusing on advances on psychiatric pharmacogenomics, and highlighting pioneering and fruitful research is well-timed and highly expected. We firmly believe that such a special issue will contribute to the field by reviewing and presenting the latest and groundbreaking findings and will help disseminate valuable knowledge and insights to the researcher as well as the clinician. The articles that will be published should deal with, but may not be limited to, the following topics:
- Pharmacogenomics of antidepressants
- Pharmacogenomics of antipsychotics
- Pharmacogenomics of mood stabilizers
- Pharmacogenomics of adverse drug reactions in psychiatry
- Implementation of pharmacogenomics in clinical practice – attitudes, barriers, perspectives, costs
- Clinical decision support tools in pharmacogenomics with emphasis in psychiatry
Dr. Evangelia Eirini Tsermpini
Dr. Maria Skokou
Prof. Dr. George Patrinos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacogenomics
- precision medicine
- antipsychotics
- antidepressants
- mood stabilizers
- lithium
- efficacy
- adverse drug reactions
- psychiatric treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
